INTRODUCTION: Obesity increases the risk of death from many adverse health outcomes and has also been linked with cancer outcomes. The impact of obesity on outcomes of advanced non-small-cell lung cancer patients is unclear. METHODS: The authors evaluated the association of body mass index (BMI) and outcomes in 2585 eligible patients enrolled in three consecutive first-line trials conducted by the Eastern Cooperative Oncology Group. BMI was categorized as underweight (BMI < 18.5 kg/m), normal weight (BMI: 18.5 to < 25 kg/m), overweight (BMI: 25 to < 30 kg/m), and obese (BMI ≥ 30 kg/m). In addition to analyzing overall and progression-free survival, reasons for treatment discontinuation were also assessed by BMI group. RESULTS: Of the patients enrolled, 4.6% were underweight, 44.1% were normal weight, 34.3% of patients were classified as overweight, and 16.9% were obese. Nonproportional hazards existed for obese patients relative to the other three groups of patients, with a change in overall survival hazard occurring at approximately 16 months. In multivariable Cox models, obese patients had superior outcomes earlier on study compared with normal/overweight patients 0.86 (HR=0.86, p=0.04; 95% CI: 0.75-0.99), but later experienced increased hazard (HR=1.54, p< 0.001; 95% CI: 1.22-1.94), indicating a time effect while undergoing treatment. CONCLUSION: Data from these three trials suggest differential outcomes associated with BMI, and additional studies of the mechanisms underlying this observation, as well as dietary and lifestyle interventions, are warranted to help optimize therapy.
INTRODUCTION:Obesity increases the risk of death from many adverse health outcomes and has also been linked with cancer outcomes. The impact of obesity on outcomes of advanced non-small-cell lung cancerpatients is unclear. METHODS: The authors evaluated the association of body mass index (BMI) and outcomes in 2585 eligible patients enrolled in three consecutive first-line trials conducted by the Eastern Cooperative Oncology Group. BMI was categorized as underweight (BMI < 18.5 kg/m), normal weight (BMI: 18.5 to < 25 kg/m), overweight (BMI: 25 to < 30 kg/m), and obese (BMI ≥ 30 kg/m). In addition to analyzing overall and progression-free survival, reasons for treatment discontinuation were also assessed by BMI group. RESULTS: Of the patients enrolled, 4.6% were underweight, 44.1% were normal weight, 34.3% of patients were classified as overweight, and 16.9% were obese. Nonproportional hazards existed for obesepatients relative to the other three groups of patients, with a change in overall survival hazard occurring at approximately 16 months. In multivariable Cox models, obesepatients had superior outcomes earlier on study compared with normal/overweight patients 0.86 (HR=0.86, p=0.04; 95% CI: 0.75-0.99), but later experienced increased hazard (HR=1.54, p< 0.001; 95% CI: 1.22-1.94), indicating a time effect while undergoing treatment. CONCLUSION: Data from these three trials suggest differential outcomes associated with BMI, and additional studies of the mechanisms underlying this observation, as well as dietary and lifestyle interventions, are warranted to help optimize therapy.
Authors: Gabriella Andreotti; Lifang Hou; Laura E Beane Freeman; Rajeev Mahajan; Stella Koutros; Joseph Coble; Jay Lubin; Aaron Blair; Jane A Hoppin; Michael Alavanja Journal: Cancer Causes Control Date: 2010-08-22 Impact factor: 2.506
Authors: Bettina Wurzinger; Martin W Dünser; Christoph Wohlmuth; Martina C Deutinger; Hanno Ulmer; Christian Torgersen; Christian A Schmittinger; Wilhelm Grander; Walter R Hasibeder Journal: Wien Klin Wochenschr Date: 2010-01 Impact factor: 1.704
Authors: Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers Journal: J Surg Res Date: 2011-05-23 Impact factor: 2.192
Authors: Benjamin T Gielda; Par Mehta; Atif Khan; James C Marsh; Thomas W Zusag; William H Warren; Mary Jo Fidler; Ross A Abrams; Philip Bonomi; Michael Liptay; L Penfield Faber Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-06 Impact factor: 7.038
Authors: David B Shackelford; Evan Abt; Laurie Gerken; Debbie S Vasquez; Atsuko Seki; Mathias Leblanc; Liu Wei; Michael C Fishbein; Johannes Czernin; Paul S Mischel; Reuben J Shaw Journal: Cancer Cell Date: 2013-01-24 Impact factor: 31.743
Authors: Xinmiao Tan; Heather H Nelson; Scott M Langevin; Michael McClean; Carmen J Marsit; Tim Waterboer; Michael Pawlita; Karl T Kelsey; Dominique S Michaud Journal: Cancer Causes Control Date: 2014-11-15 Impact factor: 2.506
Authors: Alex R Menter; Nikki M Carroll; Lori C Sakoda; Thomas Delate; Mark C Hornbrook; Rakesh K Jain; Lawrence H Kushi; Virginia P Quinn; Debra P Ritzwoller Journal: Clin Lung Cancer Date: 2016-08-20 Impact factor: 4.785
Authors: Daniel Shepshelovich; Wei Xu; Lin Lu; Aline Fares; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Xifeng Wu; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; M Catherine Brown; Geoffrey Liu; Rayjean J Hung Journal: J Thorac Oncol Date: 2019-06-01 Impact factor: 15.609